Search results for "positron"

showing 10 items of 1346 documents

Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours

2019

Abstract Introduction [68Ga]Ga-DATA-TOC is a new radiolabelled somatostatin-analogue for positron emission tomography (PET) imaging of neuroendocrine tumours. Its advantage over DOTA-conjugated compounds is the possibility for high-efficiency labelling with gallium-68 quickly at room temperature with high reliability and without the need for product purification, which enables the development of an instant kit-type labelling method. We evaluated its imaging characteristics in patients with neuroendocrine tumours in comparison to [68Ga]Ga-DOTA-TOC. Methods 19 patients imaged with [68Ga]Ga-DATA-TOC were retrospectively analysed and uptake in normal tissues was compared with a group of 19 pati…

Cancer ResearchPET-CTBiodistributionmedicine.diagnostic_testSomatostatin receptorbusiness.industry030218 nuclear medicine & medical imagingLesion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSomatostatinchemistryPositron emission tomography030220 oncology & carcinogenesismedicineMolecular MedicineDOTARadiology Nuclear Medicine and imagingIn patientmedicine.symptombusinessNuclear medicineNuclear Medicine and Biology
researchProduct

Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study.

2016

Abstract The application of radionuclide-labeled biomolecules such as monoclonal antibodies or antibody fragments for imaging purposes is called immunoscintigraphy . More specifically, when the nuclides used are positron emitters, such as zirconium-89, the technique is referred to as immuno-PET . Currently, there is an urgent need for radionuclides with a half-life which correlates well with the biological kinetics of the biomolecules under question and which can be attached to the proteins by robust labeling chemistry. 90 Nb is a promising candidate for in vivo immuno-PET , due its half-life of 14.6h and low β + energy of E mean =0.35MeV per decay. 95 Nb on the other hand, is a convenient …

Cancer ResearchPathologymedicine.medical_specialtyBiodistributionmedicine.drug_classMetaboliteNiobiumDeferoxamineMonoclonal antibody030218 nuclear medicine & medical imagingImmunoscintigraphy03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineChloridesDrug StabilityIn vivomedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionRadioisotopesOxalatesChemistryIn vitroBevacizumab030220 oncology & carcinogenesisIsotope LabelingPositron-Emission TomographyBiophysicsMolecular MedicineSpecific activityFemaleEx vivoHalf-LifeNuclear medicine and biology
researchProduct

Establishment of a [18F]-FDG-PET/MRI Imaging Protocol for Gastric Cancer PDX as a Preclinical Research Tool

2020

Purpose The utility of 18-fluordesoxyglucose positron emission tomography ([18F]-FDG-PET) combined with computer tomography or magnetic resonance imaging (MRI) in gastric cancer remains controversial and a rationale for patient selection is desired. This study aims to establish a preclinical patient-derived xenograft (PDX) based [18F]-FDG-PET/MRI protocol for gastric cancer and compare different PDX models regarding tumor growth and FDG uptake. Materials and methods Female BALB/c nu/nu mice were implanted orthotopically and subcutaneously with gastric cancer PDX. [18F]-FDG-PET/MRI scanning protocol evaluation included different tumor sizes, FDG doses, scanning intervals, and organ-specific …

Cancer ResearchPathologymedicine.medical_specialtyStandardized uptake value03 medical and health sciences0302 clinical medicinemedicineAviditymedicine.diagnostic_testbiologybusiness.industryXenograftGastroenterologyGlucose transporterCancerMagnetic resonance imagingPET scanmedicine.diseasecarbohydrates (lipids)OncologyPositron emission tomography030220 oncology & carcinogenesisbiology.proteinImmunohistochemistry030211 gastroenterology & hepatologyGLUT1Original ArticlebusinessGastric cancerGlycolysisJournal of Gastric Cancer
researchProduct

Progressive multifocal encephalopathy in a patient with non-Hodgkin follicular lymphoma

2020

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal demyelinating disease of the central nervous system caused by John Cunningham virus (JCV). We present a case report of patient with non-Hodgkin follicular lymphoma, who developed PML after hematopoietic stem cell transplantation and rituximab-bendamustine therapy. JCV DNA was proven both in peripheral blood and cerebrospinal fluid. Patient with 4 years history of follicular lymphoma presented with progressing weakness in the right arm and leg and postural instability. Magnetic resonance imaging scans showed bilateral hyperintense lesions in the cerebellum and centrum semiovale consistent with findings in PML. JCV DNA…

Cancer ResearchPathologymedicine.medical_specialtyvirusesmedicine.medical_treatmentEncephalopathyFollicular lymphomaHematopoietic stem cell transplantationImmunocompromised HostCerebrospinal fluidAntineoplastic Combined Chemotherapy ProtocolsCentrum semiovalemedicineDemyelinating diseaseHumansLymphoma Follicularmedicine.diagnostic_testbusiness.industryProgressive multifocal leukoencephalopathyHematopoietic Stem Cell TransplantationLeukoencephalopathy Progressive MultifocalDisease ManagementMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTreatment OutcomeOncologyPositron-Emission TomographyFemaleTomography X-Ray ComputedbusinessExperimental Oncology
researchProduct

Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung canc…

2018

e24184Background: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for treatment of NSCLC harboring EGFR activating mutations or secondary TKIs resistant mutation. We evaluate a new PET...

Cancer Research[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingnon-small cell lung cancer (NSCLC)[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicinemedicineIn patientComputingMilieux_MISCELLANEOUSmedicine.diagnostic_testbusiness.industryPet imagingmedicine.diseaseEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseases3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingOncologyEgfr mutationPositron emission tomography030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchbusiness030215 immunology
researchProduct

Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.

2015

Abstract Purpose Oncologic imaging is a key for successful cancer treatment. While the quality assurance (QA) of image acquisition protocols has already been focussed, QA of reading and reporting offers still room for improvement. The latter was addressed in the context of a prospective multicentre trial on fluoro-deoxyglucose (FDG)–positron-emission tomography (PET)/CT-based chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC). Material and methods An expert panel was prospectively installed performing blinded reviews of mediastinal NSCLC involvement in FDG–PET/CT. Due to a high initial reporting inter-observer disagreement, the independent data monitoring committee (I…

Cancer Researchmedicine.medical_specialtyLung NeoplasmsContext (language use)Sensitivity and SpecificityDouble-Blind MethodFluorodeoxyglucose F18Carcinoma Non-Small-Cell LungOutcome Assessment Health CaremedicineData monitoring committeeHumansMedical physicsObserver VariationPET-CTmedicine.diagnostic_testbusiness.industryReproducibility of ResultsChemoradiotherapyClinical trialOncologyPositron emission tomographyPositron-Emission TomographyRadiologybusinessTomography X-Ray ComputedQuality assuranceKappaChemoradiotherapyEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Blood flow and metabolic microenvironment of brain tumors

1994

Summarizing thesein vivo data in the context of brain tumor therapy, the following aspects are of particular importance: Low and heterogeneous tumor blood flow may — in addition to the limiting effects of the blood-brain barrier — result in compromised delivery of drugs from blood to the tissue. Low tumor pO2 reduces sensitivity to standard radiation and ‘O2-dependent’ anticancer drugs. Treatment efficacy may be further altered by changes of tumor pH. Particularly acidosis can decrease radiation sensitivity and modulate the cytotoxicity of anticancer drugs. In the following presentations, these aspects will be discussed regardingin vivo data obtained with positron emission tomography.

Cancer Researchmedicine.medical_specialtyNeurologyPartial PressureBrain tumorContext (language use)AstrocytomaPharmacologyOxygen ConsumptionRadiation sensitivitymedicineAnimalsHumansCytotoxicityAcidosismedicine.diagnostic_testBrain Neoplasmsbusiness.industryGliomaBlood flowmedicine.diseaseOxygenNeurologyOncologyRegional Blood FlowPositron emission tomographyCerebrovascular CirculationNeurology (clinical)medicine.symptombusinessJournal of Neuro-Oncology
researchProduct

Synthesis and PET studies of [11C-cyano]letrozole (Femara®), an aromatase inhibitor drug

2009

Abstract Introduction Aromatase, a member of the cytochrome P 450 family, converts androgens such as androstenedione and testosterone into estrone and estradiol, respectively. Letrozole (1-[bis-(4-cyanophenyl)methyl]-1 H -1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor ( K i =11.5 nM) that has Food and Drug Administration approval for breast cancer treatment. Here we report the synthesis of carbon-11-labeled letrozole and its assessment as a radiotracer for brain aromatase in the baboon. Methods Letrozole and its precursor (4-[(4-bromophenyl)-1 H -1,2,4-triazol-1-ylmethyl]benzonitrile) were prepared in a two-step synthesis from 4-cyanobenzyl bromide and 4-bromobenzyl bromide,…

Cancer Researchmedicine.medical_specialtymedicine.drug_classEstronePharmacologyArticlechemistry.chemical_compoundAromatasePharmacokineticsInternal medicineNitrilesmedicineAnimalsRadiology Nuclear Medicine and imagingAndrostenedioneCarbon RadioisotopesAromataseTestosteroneAromatase inhibitorbiologyChemistryAromatase InhibitorsLetrozoleBrainTriazolesEndocrinologyFree fractionIsotope LabelingPositron-Emission TomographyLetrozolebiology.proteinMolecular MedicineFemaleRadiopharmaceuticalsmedicine.drugPapio
researchProduct

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

2019

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supp…

Cancer Researchmedicine.medical_specialtypositron emission tomographymedicine.medical_treatmentReviewlcsh:RC254-282meningioma030218 nuclear medicine & medical imagingMeningioma03 medical and health sciences0302 clinical medicineNeuroimagingFunctional neuroimagingmedicineotorhinolaryngologic diseasesMedical diagnosisRadiation treatment planningGrading (tumors)neoplasmsMeningioma; Neuroimaging; Positron emission tomography; Radionuclide therapy; Somatostatin receptorneuroimagingbusiness.industryradionuclide therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasesomatostatin receptorOncologymeningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy030220 oncology & carcinogenesisRadionuclide therapyRadiologybusinessWatchful waitingCancers
researchProduct

Adipose Stromal Vascular Fraction Improves Cardiac Function in Chronic Myocardial Infarction Through Differentiation and Paracrine Activity

2012

Fresh adipose-derived cells have been shown to be effective in the treatment of acute myocardial infarction (MI), but their role in the chronic setting is unknown. We sought to determine the long-term effect of the adipose derived-stromal vascular fraction (SVF) cell transplantation in a rat model of chronic MI. MI was induced in 82 rats by permanent coronary artery ligation and 5 weeks later rats were allocated to receive an intramyocardial injection of 107 GFP-expressing fresh SVF cells or culture media as control. Heart function and tissue metabolism were determined by echocardiography and 18F-FDG-microPET, respectively, and histological studies were performed for up to 3 months after t…

Cardiac function curvemedicine.medical_specialtymedicine.medical_treatmentHeart VentriclesBiomedical EngineeringMyocardial Infarctionlcsh:MedicineAdipose tissue030204 cardiovascular system & hematologyRevascularizationRats Sprague-Dawley03 medical and health sciences0302 clinical medicineFibrosisInternal medicineParacrine CommunicationmedicineAdipocytesMyocardial RevascularizationAnimalsMyocardial infarctionAngiogenic ProteinsVentricular remodeling030304 developmental biology0303 health sciencesTransplantationTissue Inhibitor of Metalloproteinase-1Ventricular Remodelingbusiness.industrylcsh:RCell DifferentiationTissue Inhibitor of MetalloproteinasesCell BiologyStromal vascular fractionmedicine.diseaseRatsTransplantationDisease Models AnimalPhenotypeEchocardiographyPositron-Emission TomographyChronic DiseaseCardiologyCytokinesFemaleStromal CellsbusinessCell Transplantation
researchProduct